



**truscreen**  
a world without  
cervical cancer

## NZX/ASX Announcement

8 July 2024

## TruScreen Commences Major Commercial Rollout in Vietnam

### Highlights

- **10 TruScreen devices and 1,800 single-use sensors (SUS) ordered by Vietnam's Gorton Health Services (GHS)**
- **Total order value approximately NZ\$100,000**
- **Placement of TruScreen cervical cancer devices commences in key hospitals in Vietnam**
- **First major order following approval of TruScreen on the Vietnamese Ministry of Health (MOH) Technical List**
- **Vietnam has over 35 million women of screening age\***

**TruScreen Group Limited** (NZX/ASX:TRU) is pleased to announce that its Vietnamese distributor GHS has ordered 10 TruScreen cervical cancer screening devices and 1,800 SUS, marking the commencement of their major commercial rollout of TruScreen in Vietnam.

GHS has targeted 64 leading hospitals for commercial acceptance of TruScreen and will use the initial shipment of 10 devices and 1,800 SUS as the first stage in their planned rollout of TruScreen across Vietnam. The rollout builds on market acceptance and key opinion leader initiatives conducted by GHS including validation by leading hospitals. This culminated in TruScreen being included in the Vietnamese MOH Technical List. TruScreen was presented to leading gynaecologists at the Vietnam National Gynaecologic Conference on 24 May 2024.

The deployment will facilitate the screening and early detection and management of cervical cancer in Vietnam. This is a significant step towards the nationwide adoption of TruScreen in the Vietnamese public health sector.

As previously announced (NZX/ASX 20 May 2024) this initial Installation will be followed by further sales continuing through the latter half of CY2024 and into 2025.

CEO Marty Dillon commented:

*"We are excited to see Gorton Health Services take this pivotal step towards the commercialisation of TruScreen technology in Vietnam. The purchase and subsequent deployment of our devices will significantly impact the cervical cancer screening landscape in Vietnam. We are confident that TruScreen's innovative technology will contribute to achieving the World Health Organization's targets for cervical cancer screening in Vietnam."*

This announcement has been approved by the Board.

\*CIA World Fact Book women aged 15-64

**ENDS**



For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Marty Dillion  
Chief Executive Officer  
[martindillon@truscreen.com](mailto:martindillon@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

### About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra<sup>®</sup>, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140000<sup>1</sup> examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"<sup>®</sup>.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

<sup>1</sup>Based on Single Use Sensor sales.



truscreen  
a world without  
cervical cancer

Glossary:

**Pap smear** (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

**LBC** (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

**HPV (human papilloma virus) test** is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

**Sensitivity and specificity** mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)